MARC details
| 000 -LEADER |
|---|
| fixed length control field |
06365namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20260111090623.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
251222s2021 ua a|||fr|m|| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.321 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
615.321 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.12.21.M.Sc.2021.Ra.P |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Raghda Ragaa Kotb, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Potential immunotherapeutic role of curcumin, piperin and taurine combination in hepatocellular carcinoma patients / |
| Statement of responsibility, etc. |
by Raghda Ragaa kotb Abo-Elaneen ; Supervisor Prof. Dr. Ahmed Mohamed Fathi Afifi, Prof Dr. Motawa E. El-Houseini, Dr. Mona Sayed Abdellateif. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
الدور المناعي العلاجي المحتمل للكركمين والبيبرين والتورين معاً في مرضى سرطان الكبد |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2021. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
153 pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc)-Cairo University, 2021. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 88-150. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background: This is a phase II clinical trial to investigate the immunotherapeutic effect of Curcumin, <br/>Piperine, and Taurine (CPT) combination in hepatocellular carcinoma (HCC). Methods: Twenty-six <br/>HCC patients of both sexes aged (50–76 years) were recruited for administration of a daily dose of 5 g <br/>curcumin, 50 mg piperine, and 500 mg taurine divided into three doses for successive 3 months. The <br/>three components (CPT) were prepared in one capsule. Patients were assessed after each month <br/>(cycle) for the plasma levels of CD4, CD8, CD25, IL-2, IL-6, IL -12, Interferon-gamma (IFN- γ), <br/>Lactate dehydrogenase (LDH), and Vascular endothelial growth factor (VEGF), FOXP3 mRNA, and <br/>miRNA 21. Results: There was a significant increase in the plasma levels of CD4 and CD8 (P< <br/>0.001), while a significant decrease in the CD25 level (P< 0.001) after the second and third cycles <br/>compared to the baseline level. Also, there was a significant increase in the plasma levels of IL-2, IL-<br/>12, and IFN-γ (P = 0.001, P = 0.006, and P = 0.029; respectively), while there was a significant <br/>decrease in IL-6, VEGF-α, LDH, and Alpha-fetoprotein (AFP) after CPT administration compared to <br/>the baseline levels (P < 0.001, P < 0.001, P = 0.020, and P = 0.004; respectively). The expression <br/>level of miRNA-21 was significantly decreased after CPT administration compared to the baseline <br/>level [5.5±0.88, 4.1±0.78, 3±0.75, and 2.5±0.76; respectively, P < 0.001]. Though there was a <br/>noticeable decrease in FOXP3 expression after each cycle, however, it didn’t reach a significant level <br/>(5.3± 0.8, 4.2±0.76,3.2±0.67, and 2.5±0.79 respectively, P =0.184). Conclusion: CPT could exhibit a <br/>potential immune stimulating effect in HCC patients, the current trial had been registered at the <br/>National Hepatology and Tropical Medicine Research Institute (NHTMRI), with a registration <br/>number of NHTMRI-IRP 2-21on 5th January 2021 |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
الخلفيه : هذه تجربة سريرية من المرحلة الثانية لدراسة التأثير العلاجي المناعي لمزيج الكركمين والبيبرين والتورين<br/>)CPT( في سرطان الخلايا الكبدية .)HCC( الطرق: تم اخذ ستة وعشرون مري ضا بسرطان الكبد من كلا الجنسين<br/>تتراوح أعمارهم بين 76-50( عا ما) وتم اعطائهم جرعة يومية قدرها 5 جرام من الكركمين، و50 ملغ من البيبيرين، و500 ملغ من توراين مقسمة إلى ثلاث جرعات لمدة 3 أشهر متتالية. محضره فى كبسولة واحدة وبعد ذلك تم تقييم<br/>المرضى بعد كل شهر (دورة) لمستويات البلازما لـ CD4، CD8، CD25، IL-2، IL-6، IL-12، γ) (IFN-،<br/>(LDH)،. (VEGF)، FOXP3، و21 .miRNA النتائج: كان هناك زيادة ملحوظه في مستويات البلازما لـ CD4 و<br/>( P<0.001) CD8<br/>,بينما كان هناك انخفض ملحوظ في مستوى CD25 )0.001 P< بعد الجرعه الثانية و الثالثة مقارنة بما قبل بدء<br/>العلاج. أي ضا، كان هناك زيادة كبيرة في مستويات البلازما لـ IL-2 و IL-12 وIFN-γ ) 0.001 = P، 0.006 = P، و<br/>=0.029 Pعلى التوالي)، في حين كان هناك انخفاض كبير في 6 IL-، VEGF-α، LDH، والبروتين ألفا الجنيني<br/>)AFP( بعد اعطاء جرعات CPT مقارنة بما قبل بدء العلاج P=0.004) P=0.020, <0.001, P 0.001, .)P<على<br/>التوالى على الجانب الاخر انخفض مستوى miRNA-21 بشكل ملحوظ بعد إعطاء CPT مقارنة بما قبل بدء العلاج 4.1±0.78, 5.5±0.88, 3±0.75,و 2.5±0.76; على التوالى0.001 < P وعلى الرغم من وجود انخفاض ملحوظ في<br/>تعبير FOXP3 بعد كل دورة، إلا أنه لم يصل إلى مستوى كبير 5.3( ± 0.8، 4.2 ± 3.2،0.76 ± 0.67، و 2.5 ± 0.79 على التوالي، 0.184 = .)P الاستنتاج: يمكن أن ي ظهر CPT تأثي را محتملا محف زا للمناعة لدى مرضى سرطان الكبد، وقد تم تسجيل التجربة الحالية في المعهد الوطني لأبحاث أمراض الكبد والطب الاستوائي )NHTMRI(، برقم تسجيل 2-21 NHTMRI-IRP في 5 يناير .2021 |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Medicinal plants Analysis |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
تحليل النباتات الطبية |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
HCC |
| -- |
Curcumin |
| -- |
Immunomodulation |
| -- |
Piperine |
| -- |
Taurin |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ahmed Mohamed Fathi Afifi |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Motawa E. El-Houseini |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mona Sayed Abdellateif |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2021 |
| Supervisory body |
Ahmed Mohamed Fathi Afifi |
| -- |
Motawa E. El-Houseini |
| -- |
Mona Sayed Abdellateif |
| Universities |
Cairo University |
| Faculties |
Faculty of Science |
| Department |
Department of Zoology |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |